- Trials with a EudraCT protocol (280)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
280 result(s) found for: Low-density lipoprotein.
Displaying page 1 of 14.
EudraCT Number: 2022-002316-23 | Sponsor Protocol Number: CKJX839C12001B | Start Date*: 2023-01-16 | |||||||||||
Sponsor Name:Novartis Farmacéutica, S.A. | |||||||||||||
Full Title: An open-label, single arm, multicenter extension study to evaluate long-term safety and tolerability of inclisiran in participants with heterozygous or homozygous familial hypercholesterolemia who... | |||||||||||||
Medical condition: Familial Hypercholesterolemia | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) IT (Trial now transitioned) NO (Trial now transitioned) DE (Ongoing) NL (Trial now transitioned) HU (Trial now transitioned) GR (Trial now transitioned) FR (Trial now transitioned) SI (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001480-42 | Sponsor Protocol Number: MIPO3801011 | Start Date*: 2012-04-26 | |||||||||||
Sponsor Name:Genzyme Corporation and its Affiliates | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients with Familial Hypercholesterolemi... | |||||||||||||
Medical condition: Heterozygous familial hypercholesterolemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) SE (Completed) BE (Completed) GB (Completed) FR (Completed) HU (Completed) DE (Completed) CZ (Completed) GR (Completed) IT (Completed) PL (Completed) SK (Completed) NL (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000582-37 | Sponsor Protocol Number: CHOL00107 | Start Date*: 2007-09-21 | |||||||||||
Sponsor Name:Genzyme Europe BV | |||||||||||||
Full Title: A Phase 4 Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Study of Colesevelam as Add-on Therapy in Patients with Familial Hypercholesterolaemia | |||||||||||||
Medical condition: Familial hypercholesterolaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FR (Completed) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004003-23 | Sponsor Protocol Number: ISIS703802 | Start Date*: 2016-09-28 | |||||||||||||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc. | |||||||||||||||||||||||
Full Title: A Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ISIS 703802, Targeting ANGPTL3, Administered S... | |||||||||||||||||||||||
Medical condition: Heterozygous familial hypercholesterolemia and Homozygous familial hypercholesterolemia | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-000972-24 | Sponsor Protocol Number: D3561C00004 | Start Date*: 2014-08-20 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Randomized, Double blind, Placebo controlled, Multi center, Cross over Study of Rosuvastatin in Children and Adolescents (aged 6 to <18 years) with Homozygous Familial Hypercholesterolemia (HoFH) | |||||||||||||
Medical condition: Hypercholesterolemia - The current trial will study children with Homozygous Familial Hypercholesterolemia (HoFH) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) NL (Completed) BE (Completed) DK (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001023-21 | Sponsor Protocol Number: DRL-17822/CD/004 | Start Date*: 2011-06-30 | |||||||||||
Sponsor Name:DR. REDDY'S LABORATORIES LIMITED | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of DRL-17822 in Patients with Type II Hyperlipidemia | |||||||||||||
Medical condition: Hyperlipidemia Type II | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002848-41 | Sponsor Protocol Number: CAPL180A2207 | Start Date*: 2008-08-07 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled ascending dose study to evaluate the effect of APL180 on endothelial function in patients with familial hypercholesterolemia | |||||||||||||
Medical condition: familial hypercholesterolemia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002535-12 | Sponsor Protocol Number: kimcl2004-08 | Start Date*: 2004-11-19 |
Sponsor Name:Clinical Institute of Medical and Chemical Laboratory Diagnostics Graz | ||
Full Title: Fluvastatin 80 mg ret. vs combination with ezetimib 10 mg | ||
Medical condition: elevated LDL-C | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-003626-26 | Sponsor Protocol Number: 01-05-TL-475-016 | Start Date*: 2006-06-14 | |||||||||||
Sponsor Name:Takeda Europe R&D Centre Ltd | |||||||||||||
Full Title: A double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of TAK-475 or placebo when co-administered with current lipid-lowering therapy in subjects with homozygous f... | |||||||||||||
Medical condition: Treatment of primary dyslipidemia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-003807-19 | Sponsor Protocol Number: 0653A-071 | Start Date*: 2004-12-21 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia | |||||||||||||
Medical condition: Mixed hyperlipidemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) AT (Completed) GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001903-60 | Sponsor Protocol Number: EFC14643 | Start Date*: 2018-07-04 | |||||||||||
Sponsor Name:Sanofi-aventis recherche & développement | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study Followed by an Open Label Treatment Period to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents with Heterozygous Famil... | |||||||||||||
Medical condition: Hypercholesterolaemia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DK (Completed) FR (Completed) IT (Completed) DE (Completed) AT (Completed) Outside EU/EEA NL (Completed) HU (Completed) SI (Completed) ES (Completed) PL (Completed) FI (Completed) BG (Completed) CZ (Completed) NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001446-25 | Sponsor Protocol Number: FHGT002 | Start Date*: 2017-09-20 |
Sponsor Name:University of Pennsylvania | ||
Full Title: AAV8-mediated Low Density Lipoprotein Receptor (LDLR) Gene Replacement in Subjects with Homozygous Familial Hypercholesterolemia (HoFH) | ||
Medical condition: Adults with homozygous familial hypercholesterolemia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2004-002090-23 | Sponsor Protocol Number: K-111-2.02EU | Start Date*: 2005-02-03 |
Sponsor Name:Kowa Research Europe Ltd. | ||
Full Title: A phase IIa multicentre randomised double-blind, double-dummy study to evaluate the efficacy and safety of K-111 versus Fenofibrate in patients with hyperlipidaemia. | ||
Medical condition: Hyperlipidaemia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: HU (Completed) CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-004746-99 | Sponsor Protocol Number: D356NC00001 | Start Date*: 2015-02-23 |
Sponsor Name:AstraZeneca AB | ||
Full Title: An Open-Label Long-Term Extension to the Randomized, Double-blind, Placebo-controlled, Multi-center, Cross-over Study of Rosuvastatin in Children and Adolescents (aged 6 to <18 years) with Homozygo... | ||
Medical condition: Hypercholesterolemia - The current trial will study children with Homozygous Familial Hypercholesterolemia (HoFH). | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: BE (Completed) SE (Prematurely Ended) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-002358-38 | Sponsor Protocol Number: RET-D-001 | Start Date*: 2015-04-28 | |||||||||||
Sponsor Name:Travere Therapeutics, Inc. | |||||||||||||
Full Title: PROTOCOL RET-D-001: EFFICACY AND SAFETY OF SPARSENTAN (RE-021), A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, IN PATIENTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS): A RANDOMIZED... | |||||||||||||
Medical condition: FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) IT (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004084-31 | Sponsor Protocol Number: 1002-041 | Start Date*: 2023-01-23 | |||||||||||||||||||||
Sponsor Name:Esperion Therapeutics, Inc. | |||||||||||||||||||||||
Full Title: AN OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF BEMPEDOIC ACID IN PEDIATRIC PATIENTS (6 TO 17 YEARS OF AGE) WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | |||||||||||||||||||||||
Medical condition: HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Ongoing) DE (Ongoing) NL (Trial now transitioned) DK (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005473-36 | Sponsor Protocol Number: Dezember2014Version2 | Start Date*: Information not available in EudraCT |
Sponsor Name:Universitätsklinikum Freiburg | ||
Full Title: Modeling of lipoprotein in patients with familial hypercholesterolemia compared to healthy subjects | ||
Medical condition: familial hypercholesterolemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-002806-59 | Sponsor Protocol Number: LTS11717 | Start Date*: 2012-02-10 | |||||||||||
Sponsor Name:sanofi-aventis Recherche & Développement | |||||||||||||
Full Title: Long-term safety and tolerability of REGN727 / SAR236553 in high cardiovascular risk patients with hypercholesterolemia not adequately controlled with their lipid modifying therapy: a randomized, d... | |||||||||||||
Medical condition: Hypercholesterolaemia. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FI (Completed) SE (Completed) ES (Completed) PT (Completed) DE (Completed) CZ (Completed) NO (Completed) GB (Completed) NL (Completed) HU (Completed) IT (Completed) DK (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001934-19 | Sponsor Protocol Number: LPS14354 | Start Date*: 2016-02-15 | |||||||||||
Sponsor Name:Sanofi-Aventis Groupe | |||||||||||||
Full Title: A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients with Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Ris... | |||||||||||||
Medical condition: Dyslipidemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) DE (Completed) GB (Completed) SE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002810-11 | Sponsor Protocol Number: R727-CL-1609 | Start Date*: 2018-11-19 | |||||||||||||||||||||||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||||||||||||||||||||||
Full Title: Long Term Safety Study of PRALUENT in Patients with Heterozygous Familial Hypercholesterolemia or with Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk and Previously Enr... | |||||||||||||||||||||||||||||||||
Medical condition: Heterozygous Familial Hypercholesterolemia or Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: EE (Prematurely Ended) BG (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
